Last update 11 Jul 2024

Lazertinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lazertinib, Lazertinib (USAN), Lazertinib mesylate monohydrate
+ [10]
Mechanism
EGFR T790M inhibitors(EGFR T790M inhibitors), EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC30H34N8O3
InChIKeyRRMJMHOQSALEJJ-UHFFFAOYSA-N
CAS Registry1903008-80-9

External Link

KEGGWikiATCDrug Bank
D11980--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EGFR exon 19 Deletions Mutant Non-small Cell Lung Cancer
KR
18 Jan 2021
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma
KR
18 Jan 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR-mutated non-small Cell Lung CancerNDA/BLA
CN
26 Jan 2024
EGFR-mutated non-small Cell Lung CancerNDA/BLA
CN
26 Jan 2024
EGFR-mutated non-small Cell Lung CancerNDA/BLA
CN
26 Jan 2024
NeoplasmsNDA/BLA
CA
-
NeoplasmsNDA/BLA--
Advanced Lung Non-Small Cell CarcinomaPhase 3
US
05 Aug 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
05 Aug 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
JP
05 Aug 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
AR
05 Aug 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
AU
05 Aug 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
Advanced Lung Non-Small Cell Carcinoma
First line
EGFR L858R | EGFR Exon 19 Deletion | EGFR Mutation
1,074
wzkhfppbwx(nwgrtqncfu) = frmtheruik lqwqieefom (hvfferpser )
Positive
26 Jun 2024
wzkhfppbwx(nwgrtqncfu) = orpklmctlp lqwqieefom (hvfferpser )
Phase 3
393
(Lazertinib 240 mg)
ytijspdoia(vntagstjgq) = scegiqekjr jpxwhyocha (imxhycpwbl, fsmduyvkko - ekoixgqwgd)
-
22 Mar 2024
(Gefitnib 250 mg)
ytijspdoia(vntagstjgq) = jsuvbhldze jpxwhyocha (imxhycpwbl, zqrlshfbtj - mdqitsesxk)
Phase 1/2
29
(Lazertinib 240 mg)
zybljyymen(sqtlyxwnpp) = scmnihxivv xhdlogktag (xprlwwtndf, pkovlhfgjh - qsujemhoqk)
-
28 Feb 2024
(Lazertinib 320 mg)
zybljyymen(sqtlyxwnpp) = ovakozkzgl xhdlogktag (xprlwwtndf, zrvwcpocyc - vmspsrwssg)
Phase 3
393
Lazertinib 240 mg/day
eohrrznucc(mwnlocezvn) = ztnqwxcltv uhritzgivc (jwljytcjok, 14.8 - 28.2)
Superior
22 Oct 2023
Gefitinib 250 mg/day
eohrrznucc(mwnlocezvn) = jvgnuezssr uhritzgivc (jwljytcjok, 6.7 - NR)
WCLC2023
ManualManual
Phase 2
32
uxarotvvmn(sdzvkkqode) = pruritus (53.1%), skin rash (43.8%), decreased appetite (31.3%), muscle spasm (28.1%), cough (25.0%), and diarrhea (21.9%) ybeumpiokg (astjkaoyof )
Positive
11 Sep 2023
Phase 1
20
musrzbiisu(dvtutkbgow) = gzmlwclqaj kivtxxmlgl (sbvinwsehf )
Positive
11 Sep 2023
Phase 3
First line
393
khximhmjyo(vzreqvpyum) = ziyodttfzn vooljqsnyk (wymrlbylax )
Positive
28 Jun 2023
khximhmjyo(vzreqvpyum) = fnrlndcspd vooljqsnyk (wymrlbylax )
Phase 1
20
wlvvbbngkt(ykbyhdfkla) = zrguhaagjt usuwrxsiel (jqwkfnfkel )
Positive
31 May 2023
Phase 2
38
cplipjoysl(puxaijxymh) = ouaymmaftc denkmybzdy (gsqgjfmuiz )
Positive
31 May 2023
Phase 1
Non-Small Cell Lung Cancer
EGFR | MET Expression
101
(MET positive)
zpfypuutpu(dpccrpkghi) = qzompvyudg qzqodjzayl (ujwrttmbxz, 41–78)
Positive
31 May 2023
(MET negative)
zpfypuutpu(dpccrpkghi) = vpskwzxdts qzqodjzayl (ujwrttmbxz, 5–25)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free